Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-04-29 Report Publication Anno…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
2023年年度报告业绩说明会预告公告
Report Publication Announcement Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2023 Annual Report. It references the 2023 Annual Report that was previously disclosed and states the meeting will be held online for investors to better understand the annual report's details. The document is short (1180 characters) and serves as an announcement for the upcoming meeting rather than containing the actual annual report or detailed financial data. According to the 'MENU VS MEAL' rule, such announcements about report-related meetings are classified as Report Publication Announcements (RPA), not the Annual Report (10-K) itself.
2024-04-29 Chinese
第三届董事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the third board of directors of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes details about the meeting's time, place, attendance, and the approval of the 2024 first quarter report. However, the actual quarterly report is not included in the document; instead, it references that the full 2024 first quarter report is disclosed on the Beijing Stock Exchange website. The document is short (1005 characters) and serves as a meeting resolution announcement rather than the report itself. According to the 'Menu vs Meal' rule, this is an announcement related to a report, not the report itself. Therefore, the appropriate classification is a Regulatory Filing (RNS), as it does not fit other more specific categories and is a formal regulatory announcement about board decisions and report approval.
2024-04-25 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年第一季度报告" which translates to "2024 First Quarter Report." It contains detailed financial data including consolidated balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period January to March 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and management discussion of financial results and business activities. It is unaudited but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-25 Chinese
第三届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the review and approval of the company's 2024 first quarter report. It references the company's quarterly report and states that the Supervisory Board has audited and approved it. However, the document itself does not contain the actual financial statements or substantive financial data of the quarterly report; it only summarizes the approval and provides a link to the full report on the exchange website. The document length is short (1215 characters), and it serves as an announcement of the approval of the quarterly report rather than the report itself. According to the 'Menu vs Meal' rule, this is not the quarterly report but an announcement related to it. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement about the supervisory board's resolution and audit opinion on the quarterly report, without containing the report itself.
2024-04-25 Chinese
关于提请股东大会授权董事会以简易程序向特定对象发行股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding a proposal to the shareholders to authorize the board to issue new shares via a simplified procedure to specific investors. It details the type and quantity of shares, pricing, issuance method, authorization period, and related procedural authorizations. It also includes opinions from the supervisory board and independent directors, and a risk warning. The document is not a full financial report but rather a detailed announcement about a capital raising activity involving issuance of new shares. It does not contain financial statements or earnings data but focuses on the capital issuance plan and related approvals. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is substantive and not merely a brief notice or report publication announcement. Hence, the classification is CAP with high confidence.
2024-04-14 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled '年度报告' which translates to 'Annual Report' and covers the full fiscal year 2023. It includes detailed sections such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management details, industry information, corporate governance, and full financial accounting reports. The document contains comprehensive financial statements, management analysis, and audit information, including an unqualified audit opinion from a CPA firm. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed financial data, management discussion, and audit report confirms it is the official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.